Cargando…
High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers
OBJECTIVE: Tumor metabolism has always been the focus of cancer research. SLC16A1, as a key factor in catalysis of monocarboxylate transport across the plasma membrane, has been found to be associated with the occurrence and metastasis of a variety of cancers, but its prognostic significance and mec...
Autores principales: | Zhang, Ling, Song, Zheng-Shuai, Wang, Zhi-Shun, Guo, Yong-Lian, Xu, Chang-Geng, Shen, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493816/ https://www.ncbi.nlm.nih.gov/pubmed/34631536 http://dx.doi.org/10.3389/fonc.2021.706883 |
Ejemplares similares
-
MDFI is a novel biomarker for poor prognosis in LUAD
por: Chen, Pengyu, et al.
Publicado: (2022) -
Low Expression Levels of SLC22A12 Indicates a Poor Prognosis and Progresses Clear Cell Renal Cell Carcinoma
por: Xu, Jiaju, et al.
Publicado: (2021) -
SLC6A8 is a Potential Biomarker for Poor Prognosis in Lung Adenocarcinoma
por: Fan, Yongfei, et al.
Publicado: (2022) -
SKA1/2/3 is a biomarker of poor prognosis in human hepatocellular carcinoma
por: Song, Guo-Qiang, et al.
Publicado: (2022) -
Identification of Immune-Related Prognostic Biomarkers Based on the Tumor Microenvironment in 20 Malignant Tumor Types With Poor Prognosis
por: Liu, Yu, et al.
Publicado: (2020)